ImmunityBio, Inc. (IBRX) Guidance & Earnings Results
On 2026-05-07 ImmunityBio, Inc. raised guidance: "sBLA submission on track for 2026; continued revenue growth…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IBRXImmunityBio, Inc.Follow IBRX — free
—
Price chart with a free account
- Market cap
- 8.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 7 May 26 | Raised | sBLA submission on track for 2026; continued revenue growth expected |
| 23 Feb 26 | Raised | 700% YoY revenue growth; 20% QoQ growth; label expansion plans · full year |
ImmunityBio, Inc. — questions
- What guidance did ImmunityBio, Inc. give?
- On 2026-05-07: "sBLA submission on track for 2026; continued revenue growth expected"
- When does ImmunityBio, Inc. report earnings?
- ImmunityBio, Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from ImmunityBio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.